Bristol Myers' new schizophrenia drug, Cobenfy, saw strong sales in its first quarter on the market. Analysts are optimistic despite recent setbacks, emphasizing the drug's potential as a major product for the company.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing